One of the clusters shown in red included “lung cancer,” “PD-L1,” “cancer,” and “immunotherapy.” The other cluster, shown in green, generally contained terms associated with clinical oncology issues, such as “radiotherapy,” “chemotherapy,” “double-blind,” and “open-label.” The blue cluster included the names of antibodies approved by the US Food and Drug Administration (FDA), such as “nivolumab,” “pembrolizumab,” “atezolizumab,” and “ipilimumab,” and the yellow cluster included “multicenter” and “phase 3". This evidence concerns the gene CD274 and lung carcinoma.